Are you involved in preclinical drug development?

TRUE 3D Analysis in 3D - The next dimension in tissue analysis

Enter the Microenvironment with ClearLight Biotechnologies

More cost effective versus gold standard 2D thin section methods, representing contiguous and significantly more meaningful biological data

Bringing CLARITY to Preclinical Drug Development Programs.

ClearLight Biotechnologies is working with pharmaceutical, biotechnology, and academic researchers to reduce the cost and failure rates of potential drug candidates during the drug development process.

“CLARITY is powerful. It will enable researchers to study neurological diseases and disorders, focusing on diseased or damaged structures without losing a global perspective. That’s something we’ve never before been able to do in three dimensions.” Francis Collins, Director of the National Institutes of Health (NIH)

CLARITY Advantages:

  • More biologically representative analysis of drug mechanism of action by analyzing 3D tissue
  • Ability to determine tissue relationships in 3D
  • Co-development of biomarkers (CDx) linked to prognosis and prediction
  • Workflow efficiency: Efficient and more cost effective than 2D gold standard FFPE
  • Can store processed whole tissue for future analysis
  • Compatible with previously frozen, fresh, formalin-fixed, and FFPE tissue

ClearLight Biotechnologies Collaborative Custom Lab Services Include:

Three-dimensional Imaging and Quantitative Analysis in CLARITY Processed Breast Cancer Tissues

Posted on Aug 13, 2019

The tumor microenvironment can be spatially heterogenous, which makes it challenging to fully characterize with standard 2D histology-based methods. In this study, we determined the feasibility of a CLARITY tissue-processing approach to analyze biopsies from breast cancer patients. Formalin-fixed human breast cancer core-needle biopsy specimens, were embedded, lipid-cleared, and multiplexed immunostained to identify key biomarkers (pan-cytokeratin, Ki67, CD3). Confocal microscopy was then used to image the specimens after refractive index matching. These data sets were then quantitatively compared to conventional slide-based FFpe histology. Using CLARITY, the gross and cellular morphology of the tissues were well preserved, and high optical transparency was achieved, with the exception of fibrotic regions. Specific staining of various cellular and nuclear markers was achieved using optimized antibody conditions. Manually determined composite Ki67 scores from the CLARITY datasets agreed with histology results. However, the CLARITY datasets (3D) revealed variation in the intratumoral Ki67 expression that was not evident in individual FFPE sections (2D). We further demonstrated that archived FFpe clinical specimens can be CLARITY-processed, immunostained, and imaged. In short, CLARITY-processed specimens may enable a more accurate, unbiased analysis of tumor samples in comparison to conventional slide-based histology, thus allowing for improved visualization of intratumoral heterogeneity.

Let's Work Together

Do you want to escape the limitations of traditional gold standard FFPE analysis? Then you are ready to exploreTRU 3D tissue analysis in 3D for your drug development programs.

Call (800) 251-8905 or fill out the form below.

 

ClearLight Biotechnologies

Revolutionizing the Diagnostic, Prognostic, and Predictive Treatment of Disease

 

Analysis can be performed for select biomarkers, please contact us to find out if your target of interest is one of them. Imaging is currently performed on select fields of view instead of the entire sample.

Submission Guidelines

Tissue Sample Requirements: